Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-01-06 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
股东大会议事规则
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 股东大会议事规则' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Shareholders' Meeting Rules'. The content extensively details the rules, procedures, and regulations governing the conduct of shareholders' meetings, including the rights and responsibilities of shareholders, the organization and conduct of meetings, voting procedures, proposal submissions, and legal compliance. It references relevant laws and stock exchange listing rules, and covers topics such as convening meetings, voting rights, resolutions, and meeting records. There is no indication that this document is an actual meeting presentation, voting results announcement, or a financial report. Instead, it is a governance document outlining internal rules and procedures related to shareholder meetings and corporate governance. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed procedural content support this classification with high confidence.
2021-01-06 Chinese
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a public statement from the board of directors of Yunnan Watson Biotechnology Co., Ltd. nominating an independent director candidate. It details the qualifications, compliance with regulatory requirements, and declarations regarding the nominee's independence and eligibility. There is no financial data, no report of financial performance, no voting results, no legal proceedings, or other types of filings. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (7016 characters) supports it being a full statement rather than a brief announcement or certification.
2021-01-06 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is titled '云南沃森生物技术股份有限公司 董事会议事规则' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Board Meeting Rules'. The content extensively details the rules, responsibilities, composition, procedures, and powers of the company's board of directors. It references relevant laws, stock exchange listing rules, and company bylaws. There is no indication that this is a report of financial results, an announcement, or a transcript. Instead, it is a governance document outlining internal board governance practices and rules. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full governance document, not just an announcement or summary.
2021-01-06 Chinese
董事会成员多元化政策
Governance Information Classification · 95% confidence The document is titled '董事会成员多元化政策' which translates to 'Board Member Diversity Policy'. It outlines the company's policy on board diversity, including objectives, general policy, monitoring and reporting, review, disclosure, and other related matters. The content focuses on governance practices related to board composition and diversity, mentioning annual disclosure in the corporate governance report. There is no financial data, no mention of financial results, no voting results, no legal proceedings, no capital changes, and no meeting materials. The document is a governance policy statement, which fits the category of Governance Information (CGR). The document length is short and it is a policy document, not an announcement or a report publication. Therefore, the appropriate classification is CGR with high confidence.
2021-01-06 Chinese
董事、监事和高级管理人员所持公司股份及其变动管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for the holdings and changes in shares by directors, supervisors, and senior management of Yunnan Watson Biotechnology Co., Ltd. It details rules and regulations regarding shareholding, trading restrictions, reporting, disclosure, and compliance with relevant laws and stock exchange rules. The content focuses on governance and internal control over share transactions by company insiders, including reporting obligations and lock-up periods. There is no indication of financial statements, audit opinions, earnings data, or meeting materials. The document is a governance-related policy document concerning insider shareholding and trading management. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance rules, not a brief announcement or regulatory filing. Hence, the classification is CGR with high confidence.
2021-01-06 Chinese
关于子公司二价HPV疫苗收到注册现场核查通知的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a regulatory notification received about the registration site inspection for a vaccine product. It contains no financial data, no report or presentation, and is not a certification or voting result. It is a regulatory announcement about a development in the drug registration process. The document length is short (1080 characters) and it is an announcement of a regulatory event rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS).
2020-12-31 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.